Subscribe
shutterstock_591898733_ci_photos
CI Photos / Shutterstock.com
17 August 2023BiotechnologyLiz Hockley

Fed Circ affirms invalidation of two cancer treatment patents

Judges uphold PTAB decision invalidating Incept patents related to use of biodegradable filler in radiation treatment | Swedish firm Palette had challenged patents through inter partes review.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Lawsuit against Celgene, BMS and others moves forward
25 April 2023   New Jersey judge denies motion to stay antitrust action regarding blockbuster cancer drug | Defendants had argued litigation would be unnecessary and costly.
Americas
BMS and cancer centre settle patent exploitation clash
11 April 2023   Feud concerned the ownership of six immunotherapy patents | Cancer centre claimed that it was unfairly deprived of royalties.


Editor's picks

Americas
Fed Circ ruling on Wuhan import ban shakes up economic prong analysis
11 February 2025

Editor's picks

Americas
Fed Circ ruling on Wuhan import ban shakes up economic prong analysis
11 February 2025
Careers
Bristows appoints Irish patent attorney to boost UPC representation
4 February 2025
Americas
New national rankings recognise top US patent firms and lawyers
4 February 2025
Europe
UK court upholds EU SPC precedent, rejecting MSD’s appeal
30 January 2025
Americas
ADCs, TCR, and multimodal AI: Transformative trends in 2025
23 January 2025
Americas
Trump nixes Biden’s Executive Order on drug pricing
21 January 2025

More on this story

Americas
Lawsuit against Celgene, BMS and others moves forward
25 April 2023   New Jersey judge denies motion to stay antitrust action regarding blockbuster cancer drug | Defendants had argued litigation would be unnecessary and costly.
Americas
BMS and cancer centre settle patent exploitation clash
11 April 2023   Feud concerned the ownership of six immunotherapy patents | Cancer centre claimed that it was unfairly deprived of royalties.

More on this story

Americas
Lawsuit against Celgene, BMS and others moves forward
25 April 2023   New Jersey judge denies motion to stay antitrust action regarding blockbuster cancer drug | Defendants had argued litigation would be unnecessary and costly.
Americas
BMS and cancer centre settle patent exploitation clash
11 April 2023   Feud concerned the ownership of six immunotherapy patents | Cancer centre claimed that it was unfairly deprived of royalties.

More features

Hikma warns SCOTUS of ‘imminent threat’ for generic competition under ‘skinny label’ rules
Gilead deal staves off generic HIV drugs for another six years
Apple voids Omni MedSci wearable tech patent
Clifford Chance expands life sciences team with A&O Shearman hire
Vidal: ‘Erroneous’ jury instructions need to be fixed at Fed Circ
'A very good decision’: Patent industry welcomes UPC in-house reps update
Make a difference: Cast your vote in IP Diversity & Inclusion Awards 2025
Courtroom report: Regeneron’s $6bn biosimilar battle against Mylan